Announcement on the Results of Preclinical Pharmacodynamic Study of HY3003 Peptide Innovative Drug

Hybio Pharmaceutical Co., Ltd.·July 29, 2026·2 pages

✨ AI Summary

Shenzhen Hanmi Pharmaceutical announced preclinical pharmacodynamic study results for HY3003, a novel peptide drug. The study showed HY3003 achieved significant weight loss and fat reduction in animal models, outperforming existing treatments. This supports its potential in metabolic disease treatment and enhances the company's innovation capabilities.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Identification: 300199; Securities Abbreviation: Shenzhen Hanmi Pharmaceutical; Announcement No.: 2026-050

Announcement on the Results of Preclinical Pharmacodynamic Study of HY3003 Peptide Innovative Drug

The Company and its board of directors guarantee the authenticity, accuracy, and completeness of the information disclosed herein and assume no responsibility for any misrepresentations, misleading statements or material omissions.

Recently, Shenzhen Hanmi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") obtained the "HY3003 injection preclinical pharmacodynamic study results announcement" and the "HY3003 injection preclinical pharmacodynamic study results announcement". The report indicates that the newly developed GLP-1/GIP/GCGR triple agonist HY3003 injection has achieved preclinical animal pharmacodynamic results, and the relevant situation is hereby announced.

I. Background of the Project

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.